Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2254145-43-0
2. Andamertinib [inn]
3. 5x3kag7zbw
4. Orb3028552
5. Schembl21871533
6. Gtpl13732
7. Plb1004
8. Plb-1004
9. Compound 206 [wo2018228446a1]
10. 2-propenamide, N-[4-methoxy-2-[4-(3-methoxy-1-azetidinyl)-1-piperidinyl]-5-[[6-(1-methyl-1h-indazol-5-yl)-4-pyrimidinyl]amino]phenyl]-
11. N-(4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-{[6-(1-methyl-1h-indazol-5-yl)pyrimidin-4-yl]amino}phenyl)prop-2-enamide
12. N-[4-methoxy-2-[4-(3-methoxy-1-azetidinyl)-1-piperidinyl]-5-[[6-(1-methyl-1h-indazol-5-yl)-4-pyrimidinyl]amino]phenyl]-2-propenamide
13. N-[4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
| Molecular Weight | 568.7 g/mol |
|---|---|
| Molecular Formula | C31H36N8O3 |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 110 |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 913 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
57
PharmaCompass offers a list of Andamertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Andamertinib manufacturer or Andamertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Andamertinib manufacturer or Andamertinib supplier.
A Andamertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Andamertinib, including repackagers and relabelers. The FDA regulates Andamertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Andamertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Andamertinib supplier is an individual or a company that provides Andamertinib active pharmaceutical ingredient (API) or Andamertinib finished formulations upon request. The Andamertinib suppliers may include Andamertinib API manufacturers, exporters, distributors and traders.
Andamertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Andamertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Andamertinib GMP manufacturer or Andamertinib GMP API supplier for your needs.
A Andamertinib CoA (Certificate of Analysis) is a formal document that attests to Andamertinib's compliance with Andamertinib specifications and serves as a tool for batch-level quality control.
Andamertinib CoA mostly includes findings from lab analyses of a specific batch. For each Andamertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Andamertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Andamertinib EP), Andamertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Andamertinib USP).
